A phase IA, dose-escalating study of LBH589 administered intravenously in adult patients with advanced solid tumors

被引：0
|
作者：
Oizumi, S. [1 ]
Ando, Y. [2 ]
Kitagawa, K. [2 ]
Morita, S. [2 ]
Komatsu, Y. [3 ]
Yuki, S. [3 ]
Fujiwara, Y. [4 ,5 ]
Kiyota, N. [4 ,5 ]
Kobayashi, K. [6 ]
Minami, H. [4 ,5 ]
机构：
[1] Hokkaido Univ, Sch Med, Dept Med 1, Sapporo, Hokkaido 060, Japan
[2] Nagoya Univ Hosp, Dept Clin Oncol & Chemotherapy, Nagoya, Aichi, Japan
[3] Hokkaido Univ, Grad Sch Med, Dept Gastroenterol & Hematol, Sapporo, Hokkaido, Japan
[4] Kobe Univ Hosp, Kobe, Hyogo, Japan
[5] Grad Sch Med, Dept Med, Kobe, Hyogo, Japan
[6] Novartis Pharma KK, Oncol Translat Med, Tokyo, Japan
来源：
EJC SUPPLEMENTS | 2010年 / 8卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(10)72099-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：124 / 125
页数：2
相关论文
共 50 条
  • [41] A phase 1 dose escalation study of the oncolytic adenovirus enadenotucirev, administered intravenously to patients with epithelial solid tumors (EVOLVE)
    Machiels, Jean-Pascal
    Salazar, Ramon
    Rottey, Sylvie
    Duran, Ignacio
    Dirix, Luc
    Geboes, Karen
    Wilkinson-Blanc, Christine
    Pover, Gillian
    Alvis, Simon
    Champion, Brian
    Fisher, Kerry
    McElwaine-Johnn, Hilary
    Beadle, John
    Calvo, Emiliano
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [42] Phase I, dose-escalating study of elisidepsin (Irvalec®), a plasma membrane-disrupting marine antitumor agent, in combination with erlotinib in patients with advanced malignant solid tumors
    Sanjay Goel
    Santiago Viteri
    Teresa Morán
    Cinthya Coronado
    Jorge Luis Iglesias Dios
    Bernardo Miguel-Lillo
    Eva M. Fernández-García
    Rafael Rosell
    Investigational New Drugs, 2016, 34 : 75 - 83
  • [43] Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
    Mahalingam, Devalingam
    Nemunaitis, John J.
    Malik, Laeeq
    Sarantopoulos, John
    Weitman, Steven
    Sankhala, Kamalesh
    Hart, Jessica
    Kousba, Ahmed
    Gallegos, Nicole S.
    Anderson, Gavin
    Charles, John
    Rogers, Jon M.
    Senzer, Neil N.
    Mita, Alain C.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1241 - 1250
  • [44] Phase I study of intravenously administered ATI-1123, a liposomal docetaxel formulation in patients with advanced solid tumors
    Devalingam Mahalingam
    John J. Nemunaitis
    Laeeq Malik
    John Sarantopoulos
    Steven Weitman
    Kamalesh Sankhala
    Jessica Hart
    Ahmed Kousba
    Nicole S. Gallegos
    Gavin Anderson
    John Charles
    Jon M. Rogers
    Neil N. Senzer
    Alain C. Mita
    Cancer Chemotherapy and Pharmacology, 2014, 74 : 1241 - 1250
  • [45] A Phase I Study of Oral Melphalan Combined with LBH589 for Patients with Relapsed or Refractory Multiple Myeloma (MM).
    Berenson, James R.
    Yellin, Ori
    Boccia, Ralph V.
    Nassir, Youram
    Rothstein, Shellie
    Swift, Regina A.
    BLOOD, 2009, 114 (22) : 736 - 736
  • [46] A drug interaction study between dextromethorphan and panobinostat (LBH589), an orally active deacetylase inhibitor, in patients with advanced cancer
    Feld, R.
    Woo, M. M.
    Shepherd, F. A.
    Leighl, N. B.
    Elshtein, R.
    Hengelage, T.
    Hirawat, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [47] Dose-escalating study of continuative low dose of oral vinorelbine in patients with advanced breast cancer
    Felici, A.
    Russillo, M.
    Di Segni, S.
    Fabi, A.
    Ferretti, G.
    Carlini, P.
    Contestabile, M.
    Nuvoli, B.
    Sperduti, I.
    Cognetti, F.
    Papaldo, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A phase I/II study of intravenous LBH589, a novel histone deacetylase (HDAC) inhibitor, in patients (pts) with advanced hematologic malignancies.
    Giles, FJ
    Fischer, T
    Cortes, J
    Beck, J
    Ravandi-Kashani, F
    Garcia-Manero, G
    Kantarjian, HM
    Peng, B
    Rae, PE
    Laird, G
    Sharma, S
    Dugan, M
    Albitar, M
    Bhalla, KM
    BLOOD, 2004, 104 (11) : 499A - 499A
  • [49] A phase I trial of the histone deacetylase inhibitor panobinostat (LBH589) and epirubicin in patients with solid tumor malignancies.
    Moore, Amy Patricia
    Thach-Giao Truong
    Thurn, Kenneth Ted
    Thomas, Scott
    Ryan, Charles J.
    Jahan, Thierry Marie
    DuBois, Steven G.
    Chan, John K.
    Rugo, Hope S.
    Collisson, Eric Andrew
    Raha, Paromita
    Chen, Stephanie
    Reinert, Anne
    Daud, Adil
    Munster, Pamela N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [50] Phase I dose-escalating study of PM02734 in a 24-hour infusion schedule every 21 days in advanced solid tumors
    Evans, T. R.
    Oaknin, A.
    Jones, R. J.
    Vandermeeren, A.
    Coronado, C.
    Soto-Matos, A.
    Germa, J. R.
    Crawford, D.
    Frontelo, P.
    Salazar, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345